{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-24-000029","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.544996+00:00","generated_at":"2026-06-02T07:22:46.025662+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lisata Q1 net loss $5.4M; ASCEND Phase 2b data on track for Q4 2024","bullets":["Cash, equivalents and marketable securities $43.3M as of Mar 31, 2024; funding operations into early 2026.","Net loss $5.4M vs $6.2M in Q1 2023; operating expenses $6.6M, down 3.6% YoY.","Top-line data from pivotal Phase 2b ASCEND trial (mPDAC) expected Q4 2024; full data set mid-2025.","Received FDA Orphan Drug and Rare Pediatric Disease designations for certepetide in osteosarcoma.","BOLSTER (cholangiocarcinoma) enrollment completion expected Q3 2024; CENDIFOX on track for year-end 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-24-000029","json":"https://secwatch.observer/filing/0000320017-24-000029.json","markdown":"https://secwatch.observer/filing/0000320017-24-000029.md","text":"https://secwatch.observer/filing/0000320017-24-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/0000320017-24-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/clbs-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:22:46.025662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08cca268d524cea1434f5fe0ca1a7998a64b584e","claim":"LISATA THERAPEUTICS, INC. updated its the three months ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, provided a business update and reported financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001724000029/0000320017-24-000029-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}